Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1161-1166

  Hus, Marek ^a   Grzasko, Norbert ^a   Szostek, Marta ^b   Pluta, Andrzej ^c   Helbig, Grzegorz ^d   Woszczyk, Dariusz ^e   Adamczyk Cioch, Maria ^a   Jawniak, Dariusz ^a   Legiec, Wojciech ^a   Morawska, Marta ^a   Kozinska, Justyna ^a   Waciński, Piotr ^a   Dmoszynska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Podkarpackie Oncology Center Hospital   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e State Hospital   (Poland)

Author keywords

Apoptosis; Lovastatin; Multiple myeloma; Thalidomide

Indexed keywords

DEXAMETHASONE; MEVINOLIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; APOPTOSIS; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEDTIME DOSAGE; BRADYCARDIA; CANCER CELL DESTRUCTION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMBOLISM; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LETHARGY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS; AGED; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; SURVIVAL; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; LOVASTATIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 80055075364     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1276-2     Document Type: Article

References (20)

1. Blade J, Rosinol L (2008) Advances in therapy ofmultiple myeloma. Curr Opin Oncol 20:697-704
2. Hus M, Dmoszynska A, Soroka-Wojtaszko M et al (2001) Thalidomide treatment of resistant or relapsed multiple myeloma. Haematologica 86:404-408 (Pubitemid 32428501)
3. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
4. Barlogi B, Shaughnessy J, Tricot G et al (2004) Treatment ofmultiple myeloma. Blood 103:20-32
5. Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767-2772 (Pubitemid 46482069)
6. Corso A, Zappasodi P, Barbarano L et al (2009) Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leukemia Res 23:145e-149e
7. Agarwal B, Halmos B, Feoktistov AS et al (2002) Mechanism of lovastatin-induced apoptosis in intestinal intestinal epithelial cells. Carcinogenesis 23:521-528 (Pubitemid 34257633)
8. Wong WW, Clendening JW, Martirosyan A et al (2007) Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 6:1886-1897 (Pubitemid 46954066)
9. Van de Donk NW, Kamphuis MM, Van Kessel B et al (2003) Inhibition of protein geranylgeranylation induced apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 102:3354-3362 (Pubitemid 37314778)
10. Baulch-Brown C, Molloy TJ, Yeh SL et al (2007) Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 31:341-352 (Pubitemid 46091701)
11. Van de Donk NW, Kamphuls MM, Lokhorst HM et al (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362-1371
12. Feleszko W, Balkowiec E, Sieberth E et al (1999) Lovastatin and TNF alpha exhibit potentiated antitumor effects against Ha-ras transformer marine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560-567 (Pubitemid 29203053)
13. Thibault A, Samid D, Tompkims AC (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491
14. Dmoszynska A, Podhorecka M, Rolinski J et al (2004) Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Pol J Pharmacology 56:485-489 (Pubitemid 39585904)
15. Sondergaard TE, Pedersen PT, Andersen TL et al (2009) A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 27:17-22
16. Lilienfeld-Toal M, Hahn-Ast C, Furkert K et al (2008) A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 81:247-252
17. Murakami H, Handa H, Abe M et al (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 79:234-239 (Pubitemid 47231170)
18. Palumbo A, Bertola A, Falco P et al (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318-334
19. Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771 (Pubitemid 36718193)
20. Cibeira MT, Rosinol L, Ramiro L et al (2006) Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 77:486-492 (Pubitemid 44690794)